Exelixis Inc Net Income (Loss) Available to Common Stockholders, Basic
Exelixis Inc (EXEL) reported Net Income (Loss) Available to Common Stockholders, Basic of $73.21 million for the 3-month period ending 2022-09-30, per its 10-Q filed 2022-11-01.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2022-11-01
- Exelixis Inc net income (loss) available to common stockholders, basic for the quarter ending 2022-09-30 was $73.21M, a 91.63% increase year-over-year.
- Exelixis Inc net income (loss) available to common stockholders, basic for the quarter ending 2022-07-01 was $70.67M, a 26.45% decline year-over-year.
- Exelixis Inc net income (loss) available to common stockholders, basic for the quarter ending 2021-10-01 was $38.20M.
- Exelixis Inc net income (loss) available to common stockholders, basic for the quarter ending 2021-07-02 was $96.09M.
- Exelixis Inc net income (loss) available to common stockholders, basic for fiscal 2020 was $321.01M, a 53.48% decline from fiscal 2018.
- Exelixis Inc net income (loss) available to common stockholders, basic for fiscal 2018 was $690.07M, a 348.51% increase from fiscal 2017.
- Exelixis Inc net income (loss) available to common stockholders, basic for fiscal 2017 was $153.86M.
- Exelixis Inc net income (loss) available to common stockholders, basic for fiscal 2016 was -$70.22M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2022-09-30 | $73.21M 10-Q · filed 2022-11-01 | $143.88M derived: sum of 2 quarters · filed 2022-11-01 | $212.46M 10-Q · filed 2022-11-01 | |
| 2022-07-01 | $70.67M 10-Q · filed 2022-08-09 | $139.25M 10-Q · filed 2022-08-09 | ||
| 2021-10-01 | $38.20M 10-Q · filed 2022-11-01 | $134.30M derived: sum of 2 quarters · filed 2022-11-01 | $135.90M 10-Q · filed 2022-11-01 | |
| 2021-07-02 | $96.09M 10-Q · filed 2022-08-09 | $97.69M 10-Q · filed 2022-08-09 | ||
| 2020-01-03 | $321.01M 10-K · filed 2020-02-25 | |||
| 2018-12-28 | $360.09M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $486.72M derived: sum of 2 quarters · filed 2020-02-25 | $574.21M derived: sum of 3 quarters · filed 2020-02-25 | $690.07M 10-K · filed 2020-02-25 |
| 2018-09-28 | $126.63M 10-Q · filed 2018-11-01 | $214.12M derived: sum of 2 quarters · filed 2018-11-01 | $329.98M 10-Q · filed 2018-11-01 | $368.47M derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-06-29 | $87.49M 10-Q · filed 2018-08-01 | $203.35M 10-Q · filed 2018-08-01 | $241.84M derived: sum of 3 quarters · filed 2020-02-25 | $323.00M derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-03-30 | $115.86M 10-Q · filed 2018-05-02 | $154.35M derived: sum of 2 quarters · filed 2020-02-25 | $235.51M derived: sum of 3 quarters · filed 2020-02-25 | |
| 2017-12-29 | $38.49M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $119.65M derived: sum of 2 quarters · filed 2020-02-25 | $153.86M 10-K · filed 2020-02-25 | |
| 2017-09-30 | $81.16M 10-Q · filed 2017-11-01 | $115.37M 10-Q · filed 2017-11-01 | ||
| 2017-09-29 | $81.16M 10-Q · filed 2018-11-01 | $98.76M derived: sum of 2 quarters · filed 2018-11-01 | $115.37M 10-Q · filed 2018-11-01 | |
| 2017-06-30 | $17.60M 10-Q · filed 2018-08-01 | $34.24M 10-Q · filed 2017-08-02 | ||
| 2017-03-31 | $16.64M 10-Q · filed 2017-05-01 | |||
| 2016-12-30 | -$70.22M 10-K · filed 2019-02-22 | |||
| 2016-09-30 | -$11.28M 10-Q · filed 2017-11-01 | -$46.12M derived: sum of 2 quarters · filed 2017-11-01 | -$105.34M 10-Q · filed 2017-11-01 | |
| 2016-06-30 | -$34.84M 10-Q · filed 2017-08-02 | -$94.06M 10-Q · filed 2017-08-02 | ||
| 2016-03-31 | -$59.22M 10-Q · filed 2017-05-01 | |||
| 2016-01-01 | -$161.74M 10-K · filed 2018-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |